Ergoteles LLC Shattuck Labs, Inc. Transaction History

Ergoteles LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$2.5 - $4.72 $35,272 - $66,594	-14,109 Reduced 52.36%	12,839 $37,000
Q4 2022 Feb 14, 2023	SELL	$1.96 - $3.26 $148,522 - $247,033	-75,777 Reduced 73.77%	26,948 $61,000
Q3 2022 Nov 14, 2022	SELL	$2.6 - $5.52 $41,015 - $87,078	-15,775 Reduced 13.31%	102,725 $277,000
Q2 2022 Aug 12, 2022	BUY	$2.7 - $4.59 $319,950 - $543,915	118,500 New	118,500 $481,000

28.8M

300

1.2K

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $46.6M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.